Skip to content

Transanal Total Mesorectal Excision Versus Laparoscopic TME for Rectal Cancer

A Prospective Cohort Study of Transanal Laparoscopic Total Mesentery Excision Versus Conventional Laparoscopic Surgery for Rectal Cancer

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02252250
Enrollment
70
Registered
2014-09-30
Start date
2014-10-31
Completion date
2020-11-30
Last updated
2023-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal Neoplasms

Keywords

rectal cancer, laparoscopic, taTME, TME

Brief summary

To investigates the feasibility, practicability, safety and subjective as well as functional outcome of transanal minimal invasive surgery toal mesentery excision for rectal cancer.

Detailed description

Natural orifice transluminal endoscopic surgery (NOTES) give the opportunity to reduce surgical access trauma leading to a more painless surgery and enhancing a fast postoperative recovery. Experience with transanal minimal invasive surgery(TAMIS) for rectal cancer show that such NOTES procedures are feasible and safe. And also, lots of experimental studies and small case series reporting the feasibility of transanal anterior resection with single incision laparoscopic surgery(SILS) port or other devices. However any prospective feasibility study demonstrating the safety of the procedure and functional outcomes (sphincter function, sexual function, QOF) are missing. This study investigates the feasibility, practicability, safety and subjective as well as functional outcome of transanal minimal invasive total mesentery excision for rectal cancer.

Interventions

PROCEDUREconventional laparoscopic total mesentery excision

conventional laparoscopic total mesentery excision

PROCEDUREtransanal hybrid-laparoscopic total mesentery excision

transanal laparoscopic total mesentery excision for rectal cancer. Mobilize the rectum from down- to-up. Then, set a single incision laparoscopic surgery (SILS) port at the right-low abdomen to resect the lymph nodes of IMA.

Sponsors

Third Military Medical University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Biopsy-proven adenocarcinoma of the rectum * Eligible to undergo conventional laparoscopic low anterior resection or transanal hybrid-laparoscopic low anterior resection with or without a temporary diverting stoma * Node negative (N0), T1 (high risk features), T2 and T3 rectal cancer on pelvic MRI * Closest distance between tumor edge and mesorectal fascia 5mm or more based on pelvic MRI * Rectal cancer located 3-10 cm from the anal verge

Exclusion criteria

* Metastasis * Obstructing rectal cancer * Synchronous colon cancer * T4 rectal cancer not treated preoperatively with full-course chemoradiation * Pregnant or breast-feeding * Receiving any other study agents * Fecal incontinence * History of prior colorectal cancer * History of inflammatory bowel disease * History of pelvic radiation * BMI \> 40 * Large uterine fibroids * Uncontrolled intercurrent illness

Design outcomes

Primary

MeasureTime frameDescription
Adequacy of the total mesorectal excision(TME) based on standard guidelines on pathologic evaluation of TME specimens.1-6 yearsLymph nodes number; rate of positive circumferential resection margin(CRM);

Secondary

MeasureTime frameDescription
Incidence of 30-day perioperative complications including intraoperative, and postoperative complications0-30 daysbleeding, injury of adjacent organs, ileus, leakage, infection
Incidence of long-term complications1-6 yearsincision hernia,
Oncologic outcomes in subjects receiving transanal hybrid-laparoscopic total mesentery excision.1-6 yearsoverall survive rate and disease free survive rate of 3 and 5 years; recurrence rate

Other

MeasureTime frameDescription
sexual functional outcomes1-6 yearsWe examine before operation, 3 months after, 6 months after, 12 months after, 24 months after operation, by questionnaires (International Index of Erectile Function (IIEF)
Quality of life outcomes evaluation1-6 yearsWe examine before operation, 3 months after, 6 months after, 12 months after, 24 months after operation, by questionnaires (Short Form-36 (SF36) and Gastro-Intestinal Functional Outcome(GIFO)) .
defecating functional outcomes1-6 yearsconstipation score and incontinence score

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026